Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1622 1624 1626
This examiner grants 84% of resolved cases
Kristin Ann Vajda is a very high-volume examiner in Tech Center 1600 and Art Unit 1622, with 1624 resolved cases. She maintains an allowance rate of 84.0%, which is a strong indicator of success for applications on her docket. This 84.0% rate suggests that the examiner is open to finding allowable subject matter through the prosecution process. The large volume of 1624 cases ensures that these statistics are highly representative of her overall performance.
The median days to allowance for this examiner is 656, reflecting an exceptionally efficient prosecution timeline. Additionally, the data shows an interview lift of 10.9%, which provides a meaningful boost to the probability of success. This positive lift suggests that direct communication can be a very effective tool for resolving outstanding issues. The 656-day median pendency is an attractive feature for applicants seeking a quick resolution in Art Unit 1622.
For practitioners, the strategy with this examiner should include both high-quality written submissions and proactive interviewing. The 10.9% lift suggests that verbal discussions are a productive way to supplement the written record. With an 84.0% allowance rate and a 656-day median, the examiner's docket is both favorable and fast-moving. This data-driven insight allows for a more focused allocation of resources during the prosecution phase in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17282319 | Transcription Factor BRN2 Inhibitory Compounds as Therapeutics and Methods for Their Use | Final Rejection | The University of British Columbia |
| 18263772 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITORS | Non-Final OA | LG CHEM, LTD. |
| 18287646 | THERAPY FOR ALCOHOL-RELATED LIVER DISEASE | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18263582 | ENZYME INHIBITORS AND VIRAL INFECTION THERAPY | Non-Final OA | UNIVERSITY OF SOUTHERN CALIFORNIA |
| 18687448 | COMBINATIONS OF CANNABIS AND PLANT-DERIVED COMPOUNDS AS ANTI-CELL PROLIFERATION-RELATED DISEASE AGENTS | Non-Final OA | ARIEL SCIENTIFIC INNOVATIONS LTD. |
| 18687441 | TREATMENT OF NEURODEGENERATIVE DISEASES WITH HDAC INHIBITORS | Non-Final OA | CASE WESTERN RESERVE UNIVERSITY |
| 18789272 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Non-Final OA | Pfizer Inc. |
| 18701027 | IMPROVED SELECTIVE JAK2 INHIBITORS AND METHODS OF USE | Non-Final OA | Yale University |
| 18518816 | AGENT FOR PREVENTING OR AMELIORATING PRURITUS | Non-Final OA | KAO CORPORATION |
| 18943115 | 5,6,7,7a-Tetrahydrocyclopenta[f]pyrido[1,2-h][1,7] naphthyridin-11(4bH)-one Compounds and Methods of use Use (as amended) | Non-Final OA | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED |
| 18568615 | COMPOSITIONS AND METHODS FOR TREATING NON-TUBERCULOUS MYCOBACTERIAL INFECTIONS | Non-Final OA | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION |
| 18025847 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | Final Rejection | Genzyme Corporation |
| 18717846 | COMBINATION OF 5-AMINO-2,3-DIHYDRO-1,4-PHTALAZINEDIONE AND A 6'-METHOXYCINCHONAN-9-OL FOR USE IN THE TREATMENT OF CORONAVIRAL INFECTIONS | Non-Final OA | METROPHARM AG |
| 18540743 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | Final Rejection | The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Hol |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy